source
- Aclaris Therapeutics’ bosakitug fails Phase 2 eczema trial, TSLP program droppedAclaris Therapeutics announced that its experimental antibody bosakitug (ATI-045) did not meet the primary endpoint in a Phase 2 study for moderate-to-severe atopic dermatitis. The double‑blind Ad…
- Health-care providers turn to lawsuits over unpaid services as insurance costs squeeze paychecksHealth-care providers are increasingly filing lawsuits to collect unpaid fees, according to a STAT+ newsletter that cites cases such as an air-ambulance company suing a plumber and a claim involvin…